JP2014511383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511383A5 JP2014511383A5 JP2013555616A JP2013555616A JP2014511383A5 JP 2014511383 A5 JP2014511383 A5 JP 2014511383A5 JP 2013555616 A JP2013555616 A JP 2013555616A JP 2013555616 A JP2013555616 A JP 2013555616A JP 2014511383 A5 JP2014511383 A5 JP 2014511383A5
- Authority
- JP
- Japan
- Prior art keywords
- hsa
- medicament
- erbb2
- f5b6h2
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims description 41
- 102000004965 antibodies Human genes 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 35
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 102000027656 receptor tyrosine kinases Human genes 0.000 claims description 29
- 108091007921 receptor tyrosine kinases Proteins 0.000 claims description 29
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 28
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims description 28
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 27
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 27
- 229960004891 lapatinib Drugs 0.000 claims description 27
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 26
- 239000000328 estrogen antagonist Substances 0.000 claims description 24
- 238000002648 combination therapy Methods 0.000 claims description 17
- 108010010691 Trastuzumab Proteins 0.000 claims description 16
- 229960000575 trastuzumab Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003886 aromatase inhibitor Substances 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 9
- 229960003881 letrozole Drugs 0.000 claims description 9
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 8
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 8
- 229960004117 Capecitabine Drugs 0.000 claims description 8
- 229960002258 Fulvestrant Drugs 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- 229960001603 Tamoxifen Drugs 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 229960004316 cisplatin Drugs 0.000 claims description 8
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 8
- 102000015694 estrogen receptors Human genes 0.000 claims description 7
- 108010038795 estrogen receptors Proteins 0.000 claims description 7
- 239000002464 receptor antagonist Substances 0.000 claims description 7
- 230000001988 toxicity Effects 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 229960001686 Afatinib Drugs 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 5
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 5
- 229960001433 Erlotinib Drugs 0.000 claims description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 5
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 5
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 5
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 5
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 5
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 5
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 5
- 229960002448 dasatinib Drugs 0.000 claims description 5
- 229960002584 gefitinib Drugs 0.000 claims description 5
- 229960002411 imatinib Drugs 0.000 claims description 5
- 229960001346 nilotinib Drugs 0.000 claims description 5
- 229960000639 pazopanib Drugs 0.000 claims description 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 5
- 229960003787 sorafenib Drugs 0.000 claims description 5
- 229960001796 sunitinib Drugs 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000001833 anti-estrogenic Effects 0.000 claims description 4
- 230000001404 mediated Effects 0.000 claims description 4
- 229960003437 Aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
- 229950011548 FADROZOLE Drugs 0.000 claims description 3
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 3
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960001592 Paclitaxel Drugs 0.000 claims description 3
- 229960002932 anastrozole Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 229960000255 exemestane Drugs 0.000 claims description 3
- 229960004421 formestane Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 150000002596 lactones Chemical class 0.000 claims description 3
- 210000002381 Plasma Anatomy 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000006011 modification reaction Methods 0.000 claims description 2
- 229930003347 taxol Natural products 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims 2
- 229940046836 Anti-estrogens Drugs 0.000 claims 1
- 206010013710 Drug interaction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002939 deleterious Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 25
- 239000002609 media Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 6
- 108091007934 protein kinase B family Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000001640 apoptogenic Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000003104 tissue culture media Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
Description
äžèšã®åæ
æ§ããã³ãã®å±é¢ã«ãããŠã以äžã®a)ãx)ã®1ã€ä»¥äžãä»»æã§é©çšããããšãã§ããïŒa)现èæ ªã¯BT474-M3ã§ããïŒb)å¹é€ç©ã¯ã¹ãã§ãã€ãå¹é€ç©(spheroid culture)ã§ããïŒc)ãã¯ãªã¿ãã»ã«ãããã¯ä»ã®ã¿ããµã³ãŸãã¯ä»ã®ååŠçæ³è¬ããä»»æã«ã¡ãŒã«ãŒã®æ瀺ã«åŸã£ãŠãå
±æäžããïŒd)æãšã¹ããã²ã³å€ãã¡ãŒã«ãŒã®æ瀺ã«åŸã£ãŠæäžããïŒe)å容äœåããã·ã³ãããŒãŒé»å®³å€ãã¡ãŒã«ãŒã®æ瀺ã«åŸã£ãŠæäžããïŒf)ãã©ã¹ããºãããã¡ãŒã«ãŒã®æ瀺ã«åŸã£ãŠæäžããïŒg)äºéç¹ç°æ§æErbB2/æErbB3æäœãšæãšã¹ããã²ã³å€ãšã®å
±æäžã¯ãã»ãŒçžå çå¹æãŸãã¯è¶
çžå çå¹æãçã¿åºãïŒh)äºéç¹ç°æ§æErbB2/æErbB3æäœãšå容äœåããã·ã³ãããŒãŒé»å®³å€(äŸãã°ãã©ãããã)ãšã®å
±æäžã¯ãå®è³ªçã«ã»ãŒçžå çå¹æãŸãã¯è¶
çžå çå¹æãçã¿åºãïŒi)äºéç¹ç°æ§æErbB2/æErbB3æäœã¯ãSEQ ID NO:1ãå«ãæäœã§ããããã€ä»¥äžã®å®æœäŸ12ããã³13ã«èšèŒãããã¬ãžã¡ã³(äŸãã°ãæäžæ¹æ³ãæäžéãæäžééãè² è·çšéããã³ç¶æçšéããªãã³ã«æäžèšç»)ã®ããããã«åŸã£ãŠæäžããïŒj)ã©ããããã¯ã以äžã®å®æœäŸ16ã«èšèŒãããã¬ãžã¡ã³(äŸãã°ãæäžæ¹æ³ãæäžéãæäžééãè² è·çšéããã³ç¶æçšéããªãã³ã«æäžèšç»)ã®ããããã«åŸã£ãŠæäžããã
[æ¬çºæ1001]
æªæ§è «çãæãã察象ãæ²»çããæ¹æ³ã§ãã£ãŠã該察象ã«ãi)æå¹éã®æãšã¹ããã²ã³å€ãŸãã¯ii)æå¹éã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãæå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãä»»æã§æå¹éã®ãã©ã¹ããºãããšãå ±æäžãã段éãå«ããæ¹æ³ã
[æ¬çºæ1002]
äºéç¹ç°æ§æErbB2/æErbB3æäœãšãiãŸãã¯iiã®ãããããšãä»»æã§æå¹éã®ãã©ã¹ããºãããšã®çµã¿åãããã以äžã®ããã«ç¹åŸŽä»ãããããæ¬çºæ1001ã®æ¹æ³ïŒ(第1ã®æ¿åºŠã®)äºéç¹ç°æ§æErbB2/æErbB3æäœãšã(第2ã®æ¿åºŠã®)æãšã¹ããã²ã³å€ãŸãã¯(第3ã®æ¿åºŠã®)å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ãçµç¹å¹é€å¹å°ã調補ãã該å¹å°ã现èå¹é€ç©äžã®çŽ°èæ ªã®ç现èã«æ¥è§Šããããšãã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯è©²å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ããã
[æ¬çºæ1003]
现èå¹é€ç©äžã®çŽ°èæ ªã®ç现èããa)äºéç¹ç°æ§æErbB2/æErbB3æäœãå«ãŸãªãããšãé€ããŠæ¬çºæ1002ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第2ã®å¹å°ãããã³b)æãšã¹ããã²ã³å€ãå«ãŸããã€å容äœåããã·ã³ãããŒãŒé»å®³å€ãå«ãŸãªãããšãé€ããŠæ¬çºæ1002ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第3ã®å¹å°ã®ãããããšæ¥è§Šããããšãã«ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããã倧ããªçšåºŠã§ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããæ¬çºæ1002ã®æ¹æ³ã
[æ¬çºæ1004]
åèšçŽ°èæ ªãBT474-M3ã§ãããæ¬çºæ1002ãŸãã¯æ¬çºæ1003ã®æ¹æ³ã
[æ¬çºæ1005]
åèšå¹é€ç©ãã¹ãã§ãã€ãå¹é€ç©ã§ãããæ¬çºæ1002ã1003ããã³1004ã®ããããã®æ¹æ³ã
[æ¬çºæ1006]
ãã¹ãŠã®æå¹éãããŠã¹æå¹éãŸãã¯ããæå¹éã®ããããã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1007]
ãã¹ãŠã®æå¹éãããŠã¹æå¹éã§ããããã€iãŸãã¯iiã®ãããããšäºéç¹ç°æ§æErbB2/æErbB3æäœãšã®çµã¿åãããã以äžã®ããã«ç¹åŸŽä»ãããããæ¬çºæ1006ã®æ¹æ³ïŒäœç©ã枬å®ããè «çãæããBT474-M3ç°çš®ç§»æ€è «çæ æããŠã¹ã«å ±æäžãããšãã該çµã¿åããããi)ãŸãã¯ii)ã®å ±æäžã䌎ããªãããŠã¹æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã®æäžãããã32æ¥éã®å ±æäžæ²»çåŸã«è «çäœç©å¢å ãé»å®³ããäžã§å¹æçã§ããã
[æ¬çºæ1008]
ããŠã¹æå¹éã®ãã©ã¹ããºãããäºéç¹ç°æ§æErbB2/æErbB3æäœãšå ±æäžããããæ¬çºæ1007ã®æ¹æ³ã
[æ¬çºæ1009]
åèšå¯Ÿè±¡ãžã®å ±æäžãã該察象ã«ãããŠè¬ç©-è¬ç©çžäºäœçšåªä»æ¯æ§ãçã¿åºããªããæ¬çºæ1001ã1008ã®ããããã®æ¹æ³ã
[æ¬çºæ1010]
åèšå¯Ÿè±¡ãžã®å ±æäžããå®è³ªçã«çžå çãŸãã¯è¶ çžå çïŒsuperadditiveïŒå¹æããããããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1011]
åèšæãšã¹ããã²ã³å€ããšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ããŸãã¯ã¢ããã¿ãŒãŒé»å®³å€ã§ãããæ¬çºæ1001ã1010ã®ããããã®æ¹æ³ã
[æ¬çºæ1012]
åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1011ã®æ¹æ³ã
[æ¬çºæ1013]
åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ããšãã»ã¡ã¹ã¿ã³ãã¢ãã¹ãããŸãŒã«ãã¢ããã°ã«ããããããã¹ãã©ã¯ãã³ããããŸãŒã«ããã©ã«ã¡ã¹ã¿ã³ããŸãã¯ãã¡ãããŸãŒã«ã§ãããæ¬çºæ1011ã®æ¹æ³ã
[æ¬çºæ1014]
åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1013ã®æ¹æ³ã
[æ¬çºæ1015]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1001ã1014ã®ããããã®æ¹æ³ã
[æ¬çºæ1016]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããæ¬çºæ1001ã1015ã®ããããã®æ¹æ³ã
[æ¬çºæ1017]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ããããããããããããŸãã¯ãœã©ãã§ããã§ãããæ¬çºæ1001ã1016ã®ããããã®æ¹æ³ã
[æ¬çºæ1018]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1001ã1017ã®ããããã®æ¹æ³ã
[æ¬çºæ1019]
ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ãå«ãæäžã¬ãžã¡ã³ã«ããæäžããããã€ã©ãããããéæ¬ çã«æäžããããæ¬çºæ1018ã®æ¹æ³ã
[æ¬çºæ1020]
ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ã®1ã3æ¥ç®ã1ã4æ¥ç®ã1ã5æ¥ç®ã1ã6æ¥ç®ããŸãã¯1ã7æ¥ç®ã«æäžããããæ¬çºæ1019ã®æ¹æ³ã
[æ¬çºæ1021]
ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ã®1ã5æ¥ç®ã«æäžããããæ¬çºæ1020ã®æ¹æ³ã
[æ¬çºæ1022]
ã©ããããã2000ã9000mg/æ¥ã®çšéã§æäžããããæ¬çºæ1019ã1021ã®ããããã®æ¹æ³ã
[æ¬çºæ1023]
åèšçšéã3000mg/æ¥ã§ãããæ¬çºæ1022ã®æ¹æ³ã
[æ¬çºæ1024]
14æ¥æäžãµã€ã¯ã«ã®1æ¥ç®ã«æäžãããã©ããããã®çšéãè² è·çšéãå«ããæ¬çºæ1019ã1023ã®ããããã®æ¹æ³ã
[æ¬çºæ1025]
æå¹éã®ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ãããã«å«ããæ¬çºæ1001ã1024ã®ããããã®æ¹æ³ã
[æ¬çºæ1026]
æªæ§è «çã®äœµçšçæ³ã§äœ¿çšããããã®äºéç¹ç°æ§æErbB2/æErbB3æäœã§ãã£ãŠã該䜵çšçæ³ãi)æãšã¹ããã²ã³å€ãŸãã¯ii)å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ããããã®äœµçšãå«ã¿ããã€ãã©ã¹ããºããã®äœ¿çšãå«ãã§ããŠããããæäœã
[æ¬çºæ1027]
åèšæãšã¹ããã²ã³å€ããšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ããŸãã¯ã¢ããã¿ãŒãŒé»å®³å€ã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1028]
åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1026ãŸãã¯1027ã®äœµçšçæ³ã
[æ¬çºæ1029]
åèšæãšã¹ããã²ã³å€ããã¬ãããŸãŒã«ããšãã»ã¡ã¹ã¿ã³ãã¢ãã¹ãããŸãŒã«ãã¢ããã°ã«ããããããã¹ãã©ã¯ãã³ããããŸãŒã«ããã©ã«ã¡ã¹ã¿ã³ãããã³ãã¡ãããŸãŒã«ãããªã矀ããéžæãããã¢ããã¿ãŒãŒé»å®³å€ã§ãããæ¬çºæ1026ãŸãã¯1027ã®äœµçšçæ³ã
[æ¬çºæ1030]
åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1026ã1027ããã³1029ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1031]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1026ã1030ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1032]
åèšæErbB2/æErbB3æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããæ¬çºæ1026ã1031ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1033]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ãããããããããããããã³ãœã©ãã§ãããããªã矀ããéžæããããæ¬çºæ1026ã1032ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1034]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1026ã1033ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1035]
ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ã®äœµçšãããã«å«ããæ¬çºæ1026ã1034ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1036]
第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãi)第2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ãŸãã¯ii)第3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ã氎溶液ã§ãã£ãŠã第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšç¬¬2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ãŸãã¯ç¬¬3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ãçµç¹å¹é€å¹å°ã調補ãã該å¹å°ã现èå¹é€ç©äžã®çŽ°èæ ªã®ç现èã«æ¥è§Šããããšãã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ããã氎溶液ã
[æ¬çºæ1037]
现èå¹é€ç©äžã®çŽ°èæ ªã®çŽ°èããæãšã¹ããã²ã³å€ãå«ãŸããã€å容äœåããã·ã³ãããŒãŒé»å®³å€ãå«ãŸãªãããšãé€ããŠæ¬çºæ1015ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第2ã®çµç¹å¹é€å¹å°ã«æ¥è§Šããããšãããå°ãªãçšåºŠã§ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1038]
现èå¹é€ç©äžã®çŽ°èæ ªã®çŽ°èããäºéç¹ç°æ§æErbB2/æErbB3æäœãå«ãŸãªãããšãé€ããŠæ¬çºæ1015ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第3ã®çµç¹å¹é€å¹å°ã«æ¥è§Šããããšãããå°ãªãçšåºŠã§ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1039]
第4ã®æ¿åºŠã®ãã©ã¹ããºãããããã«å«ã¿ãåèšå¹å°ã第4ã®æ¿åºŠã®ãã©ã¹ããºãããããã«å«ããæ¬çºæ1036ã1038ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1040]
åèšçŽ°èæ ªãBT474-M3ã§ãããæ¬çºæ1036ã1039ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1041]
åèšå¹é€ç©ãã¹ãã§ãã€ãå¹é€ç©ã§ãããæ¬çºæ1036ã1040ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1042]
第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãi)第2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ãŸãã¯ii)第3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ã氎溶液ã§ãã£ãŠãããããã®æ¿åºŠã¯æå¹æ¿åºŠã§ããããã€è©²æ°Žæº¶æ¶²ã察象(ä»»æã§ããæ£è )ã®è¡æŒ¿ã§ããå Žåã«ã察象ã¯ã該察象ã«æœãããçæ³ã®å€æŽãå¿ èŠã«ãªãã»ã©ã«æ害ã§ããæ¯æ§ãçµéšããããšããªãããã®æ¯æ§ã¯ãäºéç¹ç°æ§æErbB2/æErbB3æäœãšæãšã¹ããã²ã³å€ãŸãã¯å容äœåããã·ã³ãããŒãŒé»å®³å€ãšã®éã®å¯Ÿè±¡ã«ãããè¬ç©-è¬ç©çžäºäœçšã«ãã£ãŠåªä»ãããã氎溶液ã
[æ¬çºæ1043]
åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1036ã1042ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1044]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1036ã1037ãããã³1039ã1043ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1045]
äºéç¹ç°æ§æErbB3,æErbB2æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããæ¬çºæ1037ã1037ãããã³1039ã1044ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1046]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ãããããããããããããã³ãœã©ãã§ããããæ¬è³ªçã«ãªã矀ããéžæããããæ¬çºæ1036ããã³1038ã1045ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1047]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1036ããã³1038ã1046ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1048]
è «ç现èãå«ãæªæ§è «çã®å¢æ®ãé»å®³ããæ¹æ³ã§ãã£ãŠãè©²è «ç现èããæ¬çºæ1036ã1047ã®ããããã®æ°Žæº¶æ¶²ã«æ¥è§Šããã段éãå«ããæ¹æ³ã
[æ¬çºæ1049]
åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1050]
ã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1051]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1052]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1053]
æå¹éã®ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ãããã«å«ããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1054]
åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1055]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1056]
ã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1057]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1058]
ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ã®äœµçšãããã«å«ããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1059]
åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1060]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1061]
ã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1062]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1063]
ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ã®äœµçšãããã«å«ããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1064]
æªæ§è «çãæãã察象ãæ²»çããæ¹æ³ã§ãã£ãŠã該察象ã«ã1)æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã2)æå¹éã®ãã©ã¹ããºããã3)æå¹éã®ã·ã¹ãã©ãã³ãããã³4)æå¹éã®ã«ãã·ã¿ãã³ãå ±æäžãã段éãå«ããæ¹æ³ã
[æ¬çºæ1065]
æªæ§è «çãæãã察象ãæ²»çããæ¹æ³ã§ãã£ãŠã該察象ã«ã1)æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã2)æå¹éã®ãã©ã¹ããºãããããã³3)æå¹éã®ãããã¯ãªã¿ãã»ã«ãå ±æäžãã段éãå«ããæ¹æ³ã
[æ¬çºæ1001]
æªæ§è «çãæãã察象ãæ²»çããæ¹æ³ã§ãã£ãŠã該察象ã«ãi)æå¹éã®æãšã¹ããã²ã³å€ãŸãã¯ii)æå¹éã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãæå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãä»»æã§æå¹éã®ãã©ã¹ããºãããšãå ±æäžãã段éãå«ããæ¹æ³ã
[æ¬çºæ1002]
äºéç¹ç°æ§æErbB2/æErbB3æäœãšãiãŸãã¯iiã®ãããããšãä»»æã§æå¹éã®ãã©ã¹ããºãããšã®çµã¿åãããã以äžã®ããã«ç¹åŸŽä»ãããããæ¬çºæ1001ã®æ¹æ³ïŒ(第1ã®æ¿åºŠã®)äºéç¹ç°æ§æErbB2/æErbB3æäœãšã(第2ã®æ¿åºŠã®)æãšã¹ããã²ã³å€ãŸãã¯(第3ã®æ¿åºŠã®)å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ãçµç¹å¹é€å¹å°ã調補ãã該å¹å°ã现èå¹é€ç©äžã®çŽ°èæ ªã®ç现èã«æ¥è§Šããããšãã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯è©²å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ããã
[æ¬çºæ1003]
现èå¹é€ç©äžã®çŽ°èæ ªã®ç现èããa)äºéç¹ç°æ§æErbB2/æErbB3æäœãå«ãŸãªãããšãé€ããŠæ¬çºæ1002ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第2ã®å¹å°ãããã³b)æãšã¹ããã²ã³å€ãå«ãŸããã€å容äœåããã·ã³ãããŒãŒé»å®³å€ãå«ãŸãªãããšãé€ããŠæ¬çºæ1002ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第3ã®å¹å°ã®ãããããšæ¥è§Šããããšãã«ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããã倧ããªçšåºŠã§ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããæ¬çºæ1002ã®æ¹æ³ã
[æ¬çºæ1004]
åèšçŽ°èæ ªãBT474-M3ã§ãããæ¬çºæ1002ãŸãã¯æ¬çºæ1003ã®æ¹æ³ã
[æ¬çºæ1005]
åèšå¹é€ç©ãã¹ãã§ãã€ãå¹é€ç©ã§ãããæ¬çºæ1002ã1003ããã³1004ã®ããããã®æ¹æ³ã
[æ¬çºæ1006]
ãã¹ãŠã®æå¹éãããŠã¹æå¹éãŸãã¯ããæå¹éã®ããããã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1007]
ãã¹ãŠã®æå¹éãããŠã¹æå¹éã§ããããã€iãŸãã¯iiã®ãããããšäºéç¹ç°æ§æErbB2/æErbB3æäœãšã®çµã¿åãããã以äžã®ããã«ç¹åŸŽä»ãããããæ¬çºæ1006ã®æ¹æ³ïŒäœç©ã枬å®ããè «çãæããBT474-M3ç°çš®ç§»æ€è «çæ æããŠã¹ã«å ±æäžãããšãã該çµã¿åããããi)ãŸãã¯ii)ã®å ±æäžã䌎ããªãããŠã¹æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã®æäžãããã32æ¥éã®å ±æäžæ²»çåŸã«è «çäœç©å¢å ãé»å®³ããäžã§å¹æçã§ããã
[æ¬çºæ1008]
ããŠã¹æå¹éã®ãã©ã¹ããºãããäºéç¹ç°æ§æErbB2/æErbB3æäœãšå ±æäžããããæ¬çºæ1007ã®æ¹æ³ã
[æ¬çºæ1009]
åèšå¯Ÿè±¡ãžã®å ±æäžãã該察象ã«ãããŠè¬ç©-è¬ç©çžäºäœçšåªä»æ¯æ§ãçã¿åºããªããæ¬çºæ1001ã1008ã®ããããã®æ¹æ³ã
[æ¬çºæ1010]
åèšå¯Ÿè±¡ãžã®å ±æäžããå®è³ªçã«çžå çãŸãã¯è¶ çžå çïŒsuperadditiveïŒå¹æããããããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1011]
åèšæãšã¹ããã²ã³å€ããšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ããŸãã¯ã¢ããã¿ãŒãŒé»å®³å€ã§ãããæ¬çºæ1001ã1010ã®ããããã®æ¹æ³ã
[æ¬çºæ1012]
åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1011ã®æ¹æ³ã
[æ¬çºæ1013]
åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ããšãã»ã¡ã¹ã¿ã³ãã¢ãã¹ãããŸãŒã«ãã¢ããã°ã«ããããããã¹ãã©ã¯ãã³ããããŸãŒã«ããã©ã«ã¡ã¹ã¿ã³ããŸãã¯ãã¡ãããŸãŒã«ã§ãããæ¬çºæ1011ã®æ¹æ³ã
[æ¬çºæ1014]
åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1013ã®æ¹æ³ã
[æ¬çºæ1015]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1001ã1014ã®ããããã®æ¹æ³ã
[æ¬çºæ1016]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããæ¬çºæ1001ã1015ã®ããããã®æ¹æ³ã
[æ¬çºæ1017]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ããããããããããããŸãã¯ãœã©ãã§ããã§ãããæ¬çºæ1001ã1016ã®ããããã®æ¹æ³ã
[æ¬çºæ1018]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1001ã1017ã®ããããã®æ¹æ³ã
[æ¬çºæ1019]
ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ãå«ãæäžã¬ãžã¡ã³ã«ããæäžããããã€ã©ãããããéæ¬ çã«æäžããããæ¬çºæ1018ã®æ¹æ³ã
[æ¬çºæ1020]
ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ã®1ã3æ¥ç®ã1ã4æ¥ç®ã1ã5æ¥ç®ã1ã6æ¥ç®ããŸãã¯1ã7æ¥ç®ã«æäžããããæ¬çºæ1019ã®æ¹æ³ã
[æ¬çºæ1021]
ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ã®1ã5æ¥ç®ã«æäžããããæ¬çºæ1020ã®æ¹æ³ã
[æ¬çºæ1022]
ã©ããããã2000ã9000mg/æ¥ã®çšéã§æäžããããæ¬çºæ1019ã1021ã®ããããã®æ¹æ³ã
[æ¬çºæ1023]
åèšçšéã3000mg/æ¥ã§ãããæ¬çºæ1022ã®æ¹æ³ã
[æ¬çºæ1024]
14æ¥æäžãµã€ã¯ã«ã®1æ¥ç®ã«æäžãããã©ããããã®çšéãè² è·çšéãå«ããæ¬çºæ1019ã1023ã®ããããã®æ¹æ³ã
[æ¬çºæ1025]
æå¹éã®ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ãããã«å«ããæ¬çºæ1001ã1024ã®ããããã®æ¹æ³ã
[æ¬çºæ1026]
æªæ§è «çã®äœµçšçæ³ã§äœ¿çšããããã®äºéç¹ç°æ§æErbB2/æErbB3æäœã§ãã£ãŠã該䜵çšçæ³ãi)æãšã¹ããã²ã³å€ãŸãã¯ii)å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ããããã®äœµçšãå«ã¿ããã€ãã©ã¹ããºããã®äœ¿çšãå«ãã§ããŠããããæäœã
[æ¬çºæ1027]
åèšæãšã¹ããã²ã³å€ããšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ããŸãã¯ã¢ããã¿ãŒãŒé»å®³å€ã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1028]
åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1026ãŸãã¯1027ã®äœµçšçæ³ã
[æ¬çºæ1029]
åèšæãšã¹ããã²ã³å€ããã¬ãããŸãŒã«ããšãã»ã¡ã¹ã¿ã³ãã¢ãã¹ãããŸãŒã«ãã¢ããã°ã«ããããããã¹ãã©ã¯ãã³ããããŸãŒã«ããã©ã«ã¡ã¹ã¿ã³ãããã³ãã¡ãããŸãŒã«ãããªã矀ããéžæãããã¢ããã¿ãŒãŒé»å®³å€ã§ãããæ¬çºæ1026ãŸãã¯1027ã®äœµçšçæ³ã
[æ¬çºæ1030]
åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1026ã1027ããã³1029ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1031]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1026ã1030ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1032]
åèšæErbB2/æErbB3æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããæ¬çºæ1026ã1031ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1033]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ãããããããããããããã³ãœã©ãã§ãããããªã矀ããéžæããããæ¬çºæ1026ã1032ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1034]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1026ã1033ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1035]
ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ã®äœµçšãããã«å«ããæ¬çºæ1026ã1034ã®ããããã®äœµçšçæ³ã
[æ¬çºæ1036]
第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãi)第2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ãŸãã¯ii)第3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ã氎溶液ã§ãã£ãŠã第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšç¬¬2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ãŸãã¯ç¬¬3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ãçµç¹å¹é€å¹å°ã調補ãã該å¹å°ã现èå¹é€ç©äžã®çŽ°èæ ªã®ç现èã«æ¥è§Šããããšãã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ããã氎溶液ã
[æ¬çºæ1037]
现èå¹é€ç©äžã®çŽ°èæ ªã®çŽ°èããæãšã¹ããã²ã³å€ãå«ãŸããã€å容äœåããã·ã³ãããŒãŒé»å®³å€ãå«ãŸãªãããšãé€ããŠæ¬çºæ1015ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第2ã®çµç¹å¹é€å¹å°ã«æ¥è§Šããããšãããå°ãªãçšåºŠã§ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1038]
现èå¹é€ç©äžã®çŽ°èæ ªã®çŽ°èããäºéç¹ç°æ§æErbB2/æErbB3æäœãå«ãŸãªãããšãé€ããŠæ¬çºæ1015ã®å¹å°ãšæ¬è³ªçã«åãã§ãã第3ã®çµç¹å¹é€å¹å°ã«æ¥è§Šããããšãããå°ãªãçšåºŠã§ã现èæé·ãããã¯çŽ°èå¢æ®ãŸãã¯è©²çŽ°èå ã§ã®pErbB3ã®ç£çãããã¯pAKTã®ç£çãé»å®³ããããããããã¯å¹é€ç©äžã®ã¢ãããŒã·ã¹æ§ã§ãã现èã®å²åãå¢å ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1039]
第4ã®æ¿åºŠã®ãã©ã¹ããºãããããã«å«ã¿ãåèšå¹å°ã第4ã®æ¿åºŠã®ãã©ã¹ããºãããããã«å«ããæ¬çºæ1036ã1038ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1040]
åèšçŽ°èæ ªãBT474-M3ã§ãããæ¬çºæ1036ã1039ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1041]
åèšå¹é€ç©ãã¹ãã§ãã€ãå¹é€ç©ã§ãããæ¬çºæ1036ã1040ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1042]
第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãi)第2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ãŸãã¯ii)第3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãå«ã氎溶液ã§ãã£ãŠãããããã®æ¿åºŠã¯æå¹æ¿åºŠã§ããããã€è©²æ°Žæº¶æ¶²ã察象(ä»»æã§ããæ£è )ã®è¡æŒ¿ã§ããå Žåã«ã察象ã¯ã該察象ã«æœãããçæ³ã®å€æŽãå¿ èŠã«ãªãã»ã©ã«æ害ã§ããæ¯æ§ãçµéšããããšããªãããã®æ¯æ§ã¯ãäºéç¹ç°æ§æErbB2/æErbB3æäœãšæãšã¹ããã²ã³å€ãŸãã¯å容äœåããã·ã³ãããŒãŒé»å®³å€ãšã®éã®å¯Ÿè±¡ã«ãããè¬ç©-è¬ç©çžäºäœçšã«ãã£ãŠåªä»ãããã氎溶液ã
[æ¬çºæ1043]
åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1036ã1042ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1044]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1036ã1037ãããã³1039ã1043ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1045]
äºéç¹ç°æ§æErbB3,æErbB2æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããæ¬çºæ1037ã1037ãããã³1039ã1044ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1046]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ãããããããããããããã³ãœã©ãã§ããããæ¬è³ªçã«ãªã矀ããéžæããããæ¬çºæ1036ããã³1038ã1045ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1047]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1036ããã³1038ã1046ã®ããããã®æ°Žæº¶æ¶²ã
[æ¬çºæ1048]
è «ç现èãå«ãæªæ§è «çã®å¢æ®ãé»å®³ããæ¹æ³ã§ãã£ãŠãè©²è «ç现èããæ¬çºæ1036ã1047ã®ããããã®æ°Žæº¶æ¶²ã«æ¥è§Šããã段éãå«ããæ¹æ³ã
[æ¬çºæ1049]
åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1050]
ã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1051]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1052]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1053]
æå¹éã®ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ãããã«å«ããæ¬çºæ1001ã®æ¹æ³ã
[æ¬çºæ1054]
åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1055]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1056]
ã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1057]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1058]
ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ã®äœµçšãããã«å«ããæ¬çºæ1026ã®äœµçšçæ³ã
[æ¬çºæ1059]
åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1060]
åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1061]
ã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1062]
åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1063]
ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ã®äœµçšãããã«å«ããæ¬çºæ1036ã®æ°Žæº¶æ¶²ã
[æ¬çºæ1064]
æªæ§è «çãæãã察象ãæ²»çããæ¹æ³ã§ãã£ãŠã該察象ã«ã1)æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã2)æå¹éã®ãã©ã¹ããºããã3)æå¹éã®ã·ã¹ãã©ãã³ãããã³4)æå¹éã®ã«ãã·ã¿ãã³ãå ±æäžãã段éãå«ããæ¹æ³ã
[æ¬çºæ1065]
æªæ§è «çãæãã察象ãæ²»çããæ¹æ³ã§ãã£ãŠã該察象ã«ã1)æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã2)æå¹éã®ãã©ã¹ããºãããããã³3)æå¹éã®ãããã¯ãªã¿ãã»ã«ãå ±æäžãã段éãå«ããæ¹æ³ã
Claims (31)
- i)æå¹éã®æãšã¹ããã²ã³å€ãŸãã¯ii)æå¹éã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããšãæå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœãšãä»»æã§æå¹éã®ãã©ã¹ããºãããšã®çµã¿åãããå«ããæªæ§è «çãæãã察象ãæ²»çããããã®å»è¬ã§ãã£ãŠãi)ãŸãã¯ii)ã®ãããããšä»»æã§ãã©ã¹ããºããããäºéç¹ç°æ§æErbB2/æErbB3æäœãšçµã¿åãããŠæäžãããããã«äœ¿çšããããåèšå»è¬ã
- ãã¹ãŠã®æå¹éãããŠã¹æå¹éãŸãã¯ããæå¹éã®ããããã§ãããè«æ±é 1èšèŒã®å»è¬ã
- åèšå¯Ÿè±¡ã«ãããŠè¬ç©-è¬ç©çžäºäœçšåªä»æ¯æ§ãçã¿åºããªããè«æ±é 1ãŸãã¯2èšèŒã®å»è¬ã
- å®è³ªçã«çžå çãŸãã¯è¶ çžå çïŒsuperadditiveïŒå¹æããããããè«æ±é 1èšèŒã®å»è¬ã
- åèšæãšã¹ããã²ã³å€ããšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ããŸãã¯ã¢ããã¿ãŒãŒé»å®³å€ã§ãããè«æ±é 1ã4ã®ããããäžé èšèŒã®å»è¬ã
- åèšãšã¹ããã²ã³å容äœã¢ã³ã¿ãŽãã¹ãããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããè«æ±é 5èšèŒã®å»è¬ã
- åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ããšãã»ã¡ã¹ã¿ã³ãã¢ãã¹ãããŸãŒã«ãã¢ããã°ã«ããããããã¹ãã©ã¯ãã³ããããŸãŒã«ããã©ã«ã¡ã¹ã¿ã³ããŸãã¯ãã¡ãããŸãŒã«ã§ãããè«æ±é 5èšèŒã®å»è¬ã
- åèšã¢ããã¿ãŒãŒé»å®³å€ãã¬ãããŸãŒã«ã§ãããè«æ±é 7èšèŒã®å»è¬ã
- åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããè«æ±é 1ã8ã®ããããäžé èšèŒã®å»è¬ã
- åèšäºéç¹ç°æ§æErbB2/æErbB3æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããè«æ±é 1ã9ã®ããããäžé èšèŒã®å»è¬ã
- åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ããããããããããããŸãã¯ãœã©ãã§ããã§ãããè«æ±é 1ã10ã®ããããäžé èšèŒã®å»è¬ã
- åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããè«æ±é 1ã11ã®ããããäžé èšèŒã®å»è¬ã
- ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ãå«ãæäžã¬ãžã¡ã³ã«ããå»è¬ã®äœ¿çšãç¹åŸŽãšãããã€ã©ãããããéæ¬ çãªäœ¿çšãç¹åŸŽãšãããè«æ±é 12èšèŒã®å»è¬ã
- ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ã®1ã3æ¥ç®ã1ã4æ¥ç®ã1ã5æ¥ç®ã1ã6æ¥ç®ããŸãã¯1ã7æ¥ç®ã®å»è¬ã®äœ¿çšãç¹åŸŽãšãããè«æ±é 13èšèŒã®å»è¬ã
- ã©ããããã14æ¥æäžã¹ã±ãžã¥ãŒã«ã®1ã5æ¥ç®ã®å»è¬ã®äœ¿çšãç¹åŸŽãšãããè«æ±é 14èšèŒã®å»è¬ã
- ã©ããããã2000ã9000mg/æ¥ã®çšéã®å»è¬ã®äœ¿çšãç¹åŸŽãšãããè«æ±é 13ã15ã®ããããäžé èšèŒã®å»è¬ã
- åèšçšéã3000mg/æ¥ã§ãããè«æ±é 16èšèŒã®å»è¬ã
- 14æ¥æäžãµã€ã¯ã«ã®1æ¥ç®ã®å»è¬ã®äœ¿çšã®ããã®ã©ããããã®çšéãè² è·çšéãå«ãããšãç¹åŸŽãšãããè«æ±é 13ã17ã®ããããäžé èšèŒã®å»è¬ã
- æå¹éã®ã«ãã·ã¿ãã³ããã³/ãŸãã¯ã·ã¹ãã©ãã³ãããã«å«ããè«æ±é 1ã18ã®ããããäžé èšèŒã®å»è¬ã
- æå¹éã®ãã©ã¹ããºãããšã®çµã¿åãããããã«å«ããè«æ±é 1ã19ã®ããããäžé èšèŒã®å»è¬ã
- äºéç¹ç°æ§æErbB2/æErbB3æäœãi)æãšã¹ããã²ã³å€ãŸãã¯ii)å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããããã³ä»»æã§ãã©ã¹ããºããããæªæ§è «çãæãã察象ã«å ±æäžããããè«æ±é 1ã20ã®ããããäžé èšèŒã®å»è¬ã
- äºéç¹ç°æ§æErbB2/æErbB3æäœãi)æãšã¹ããã²ã³å€ãŸãã¯ii)å容äœåããã·ã³ãããŒãŒé»å®³å€ã®ãããããããã³ä»»æã§ãã©ã¹ããºããããæªæ§è «çãæãã察象ã«å¥ã ã«æäžããããè«æ±é 1ã20ã®ããããäžé èšèŒã®å»è¬ã
- 第1ã®æ¿åºŠã®äºéç¹ç°æ§æErbB2/æErbB3æäœã§ãã第1ã®æ§æèŠçŽ ãšã第2ã®æ¿åºŠã®æãšã¹ããã²ã³å€ã§ãã第2ã®æ§æèŠçŽ ãŸãã¯ç¬¬3ã®æ¿åºŠã®å容äœåããã·ã³ãããŒãŒé»å®³å€ã§ãã第3ã®æ§æèŠçŽ ã®ãããããšãå«ã氎溶液ã§ãã£ãŠãããããã®æ¿åºŠã¯æå¹æ¿åºŠã§ããããã€è©²æ°Žæº¶æ¶²ã察象ã®è¡æŒ¿ã§ããå Žåã«ã察象ã¯ã該察象ã«æœãããçæ³ã®å€æŽãå¿ èŠã«ãªãã»ã©ã«æ害ã§ããæ¯æ§ãçµéšããããšããªãããã®æ¯æ§ã¯ãäºéç¹ç°æ§æErbB2/æErbB3æäœãšæãšã¹ããã²ã³å€ãŸãã¯å容äœåããã·ã³ãããŒãŒé»å®³å€ãšã®éã®å¯Ÿè±¡ã«ãããè¬ç©-è¬ç©çžäºäœçšã«ãã£ãŠåªä»ãããã氎溶液ã
- åèšæãšã¹ããã²ã³å€ããã«ãã¹ãã©ã³ããŸãã¯ã¿ã¢ãã·ãã§ã³ã§ãããè«æ±é 23èšèŒã®æ°Žæº¶æ¶²ã
- åèšäºéç¹ç°æ§æErbB2/æErbB3æäœãSEQ ID NO:1ã«èšèŒã®ã¢ããé žé åãå«ããè«æ±é 23ãŸãã¯24èšèŒã®æ°Žæº¶æ¶²ã
- äºéç¹ç°æ§æErbB3,æErbB2æäœããA5-HSA-ML3.9ãML3.9-HSA-A5ãA5-HSA-B1D2ãB1D2-HSA-A5ãB12-HSA-B1D2ãB1D2-HSA-B12ãA5-HSA-F5B6H2ãF5B6H2-HSA-A5ãH3-HSA-F5B6H2ãF5B6H2-HSA-H3ãF4-HSA-F5B6H2ãF5B6H2-HSA-F4ãB1D2-HSA-H3ãããã³H3-HSA-B1D2ãããªã矀ããéžæããããè«æ±é 23ã25ã®ããããäžé èšèŒã®æ°Žæº¶æ¶²ã
- åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ããšã«ãããããã¢ãã¡ããããããµããããã²ãã£ããããã€ãããããããŸããããã©ãããããã¹ãããããããããããããã³ãœã©ãã§ããããæ¬è³ªçã«ãªã矀ããéžæããããè«æ±é 23ã26ã®ããããäžé èšèŒã®æ°Žæº¶æ¶²ã
- åèšå容äœåããã·ã³ãããŒãŒé»å®³å€ãã©ããããã§ãããè«æ±é 23ã27ã®ããããäžé èšèŒã®æ°Žæº¶æ¶²ã
- åèšæ§æèŠçŽ ãè«æ±é 23ã28ã®ããããäžé èšèŒã®æ°Žæº¶æ¶²ãšããŠåŠæ¹ããããè«æ±é 1ã21ã®ããããäžé èšèŒã®çµæç©ã
- æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã§ãã第1ã®æ§æèŠçŽ ãæå¹éã®ãã©ã¹ããºããã§ãã第2ã®æ§æèŠçŽ ãæå¹éã®ã·ã¹ãã©ãã³ã§ãã第3ã®æ§æèŠçŽ ãããã³æå¹éã®ã«ãã·ã¿ãã³ã§ãã第4ã®æ§æèŠçŽ ã®çµã¿åãããå«ããæªæ§è «çãæãã察象ãæ²»çããããã®å»è¬ã§ãã£ãŠã該å»è¬ã®æ§æèŠçŽ ã䜵çšçæ³ã®ããã«äœ¿çšããããã€è©²æ§æèŠçŽ ãæªæ§è «çãæãã察象ã«å ±æäžãŸãã¯å¥ã ã«æäžããããåèšå»è¬ã
- æå¹éã®äºéç¹ç°æ§æErbB2/æErbB3æäœã§ãã第1ã®æ§æèŠçŽ ãæå¹éã®ãã©ã¹ããºããã§ãã第2ã®æ§æèŠçŽ ãããã³æå¹éã®ãããã¯ãªã¿ãã»ã«ã§ãã第3ã®æ§æèŠçŽ ã®çµã¿åãããå«ããæªæ§è «çãæãã察象ãæ²»çããããã®å»è¬ã§ãã£ãŠã該å»è¬ã®æ§æèŠçŽ ã䜵çšçæ³ã®ããã«äœ¿çšããããã€è©²æ§æèŠçŽ ãæªæ§è «çãæãã察象ã«å ±æäžãŸãã¯å¥ã ã«æäžããããåèšå»è¬ã
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161446326P | 2011-02-24 | 2011-02-24 | |
US61/446,326 | 2011-02-24 | ||
US201161470848P | 2011-04-01 | 2011-04-01 | |
US61/470,848 | 2011-04-01 | ||
PCT/US2012/026602 WO2012116317A2 (en) | 2011-02-24 | 2012-02-24 | Combination therapies comprising anti-erbb3 agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014511383A JP2014511383A (ja) | 2014-05-15 |
JP2014511383A5 true JP2014511383A5 (ja) | 2015-04-16 |
Family
ID=46721477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013555616A Pending JP2014511383A (ja) | 2011-02-24 | 2012-02-24 | æïœïœïŒ¢ïŒå€ãå«ã䜵çšçæ³ |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140056898A1 (ja) |
EP (1) | EP2678359A4 (ja) |
JP (1) | JP2014511383A (ja) |
KR (1) | KR20140053865A (ja) |
CN (1) | CN103547598A (ja) |
AU (1) | AU2012222094A1 (ja) |
BR (1) | BR112013021660A2 (ja) |
CA (1) | CA2828099A1 (ja) |
IL (1) | IL228095A0 (ja) |
MX (1) | MX2013009732A (ja) |
WO (1) | WO2012116317A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53042B (en) | 2007-02-16 | 2014-04-30 | Merrimack Pharmaceuticals Inc. | ANTIBODIES AGAINST ERBB3 AND THEIR USES |
SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
CN103429262A (zh) * | 2011-03-15 | 2013-12-04 | æ¢ é麊å å¶è¯è¡ä»œæéå ¬åž | å æ对erbbéåŸæå¶åçææ§ |
AU2013259053A1 (en) * | 2012-05-11 | 2015-01-15 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scFv conjugates in combination with anti-cancer therapeutics |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
EP3110846B1 (en) | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | ã¡ã«ã¹ ãã ããŒãŒ ãã§ã³ããŒãã·ã£ãã | çã®æé·ãæå¶ããçµååå |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
BR112019024230A2 (pt) * | 2017-05-17 | 2020-06-09 | Merus N.V. | combinação de um anticorpo bispecÃfico erbb-2 / erbb-3 com terapia endócrina para câncer de mama |
CA3072404A1 (en) | 2017-08-09 | 2019-02-14 | Merus N.V. | Antibodies that bind egfr and cmet |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102282168A (zh) * | 2008-11-18 | 2011-12-14 | æ¢ é麊å å¶è¯è¡ä»œæéå ¬åž | 人è¡æž çœèçœæ¥å€Žä»¥åå ¶ç»åç© |
CA2819554A1 (en) * | 2010-12-10 | 2012-06-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates |
-
2012
- 2012-02-24 AU AU2012222094A patent/AU2012222094A1/en not_active Abandoned
- 2012-02-24 EP EP12749889.7A patent/EP2678359A4/en not_active Withdrawn
- 2012-02-24 CN CN201280019977.7A patent/CN103547598A/zh active Pending
- 2012-02-24 BR BR112013021660A patent/BR112013021660A2/pt not_active IP Right Cessation
- 2012-02-24 WO PCT/US2012/026602 patent/WO2012116317A2/en active Application Filing
- 2012-02-24 CA CA2828099A patent/CA2828099A1/en not_active Abandoned
- 2012-02-24 KR KR1020137025188A patent/KR20140053865A/ko not_active Application Discontinuation
- 2012-02-24 US US14/001,448 patent/US20140056898A1/en not_active Abandoned
- 2012-02-24 JP JP2013555616A patent/JP2014511383A/ja active Pending
- 2012-02-24 MX MX2013009732A patent/MX2013009732A/es not_active Application Discontinuation
-
2013
- 2013-08-22 IL IL228095A patent/IL228095A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014511383A5 (ja) | ||
JP6787792B2 (ja) | ããã®åŠçœ®ã®ããã®äœµçšæ²»ç | |
TWI794171B (zh) | ïœïœïœæå¶åèïœïœ-ïœïŒæå¶åä¹çµåæ²»ç | |
Zhao et al. | Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo | |
EP3060200B1 (en) | Tyrosine derivatives and compositions comprising them | |
JP2018505169A5 (ja) | ||
WO2013152034A1 (en) | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies | |
RU2018103064A (ru) | ÐПЌбОМаÑÐžÑ ÐžÐœÐ³ÐžÐ±ÐžÑПÑа hdac О аМÑО-pd-l1-аМÑОÑела ÐŽÐ»Ñ Ð»ÐµÑÐµÐœÐžÑ Ð·Ð»ÐŸÐºÐ°ÑеÑÑвеММПй ПпÑÑ ÐŸÐ»Ðž | |
JP2018508516A5 (ja) | ||
RU2014141362A (ru) | ÐПЌбОМОÑÐŸÐ²Ð°ÐœÐœÐ°Ñ ÑеÑÐ°Ð¿ÐžÑ Ð¿ÑПлОÑеÑаÑОвМÑÑ ÐœÐ°ÑÑÑеМОй | |
BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
CN106456635A (zh) | Mdm2æå¶åçéŽæç»è¯ | |
RU2014144254A (ru) | ÐПЌбОМОÑПваММÑе пÑПЎÑкÑÑ, ÑПЎеÑжаÑОе ОМгОбОÑПÑÑ ÑОÑПзОМкОМаз, О ÐžÑ Ð¿ÑОЌеМеМОе | |
JP2020505433A5 (ja) | ||
AU2010234968B2 (en) | Treatment regimen utilizing neratinib for breast cancer | |
JP2014525465A5 (ja) | ||
TW202214243A (zh) | è¥¿å¥§çŸ å°Œè¯åå ç«æª¢æ¥é»æ補ååšæè «ç€æ²»çäžçæçš | |
JP2021502345A (ja) | æããå€ | |
JP2019514864A (ja) | èçã®æ²»çæ¹æ³ | |
JP2022506829A (ja) | ãšãªããªã³ãšéžæçïœïœïœïŒïŒïŒé»å®³å€ãšã®çµåãã䜿çšããçã®åŠçœ®ã®ããã®æ²»çã¬ãžã¡ã³ | |
CA3116731A1 (en) | Combinations for immune-modulation in cancer treatment | |
AU2014248377B2 (en) | Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
UA121389C2 (uk) | ÐПÑвЌÑÑÐœÑ ÑМгÑбÑÑПÑО пÑПÑеаÑПЌ ÐŽÐ»Ñ Ð·Ð°ÑÑПÑÑÐ²Ð°ÐœÐœÑ Ð¿ÑÑÐ»Ñ Ð¿ÐµÑÐ²ÐžÐœÐœÐŸÑ Ð¿ÑПÑОÑÐ°ÐºÐŸÐ²ÐŸÑ ÑеÑапÑÑ | |
RU2015139515A (ru) | ÐПЌбОМОÑПваММПе леÑеМОе | |
JP7311177B2 (ja) | ïŒïŒ®ïŒ¯ïŒ²ïŒïŒÎ±ã¢ã³ããã¹ã¿ã³è¬ç©ãšæããè¬ç©ãšã®äœµçš |